In the context of non-surgical bleeding, an initial coagulation screen is useful as a guide to further management. It usually consists of platelet count, prothrombin time, activated partial thromboplastin time, thrombin time and fibrinogen level. When the results are normal, underlying coagulation disorders which evade the scope of the initial coagulation screen are suspected. With the knowledge of the principles of the tests used for the initial coagulation screen and the awareness of the rare coagulation disorders which will not affect the initial results, a systematic approach can be applied in the management of such patients. This review aims to highlight the importance of pitfalls in the interpretation of the initial coagulation screening results and provides a brief summary on the coagulation disorders without a deranged initial coagulation screen.
INTRODUCTION
Blood is maintained in the fluid state in the circulatory system by a delicate balance among the factors influencing haemostasis and natural anticoagulants. Extravasation of blood or bleeding, is the consequence of a breach of vascular integrity which physiologically then triggers haemostatic mechanisms mediated by a combination of smooth muscle contraction, platelet plugging and effective clot formation. Excessive bleeding occurs when there is extensive trauma or large vessel injury which overwhelms normal haemostatic mechanisms or defects to this complex system. The former is usually amenable to surgical procedures or mechanical measures that directly secure haemostasis. Non-surgical bleeding, in contrast usually refers to bleeding that is spontaneous or out of proportion to the degree of trauma or tissue injury. In such situations, an abnormality of the haemostatic mechanism which can be intrinsic or acquired is usually suspected. Elucidating and managing such bleedings can potentially be challenging.
Primary and secondary haemostasis is influenced by a number of components including platelets, von Willebrand factors, vascular endothelium, coagulation factors and fibrinolytic system. Disruption of function or quantity of any of these components can lead to abnormal bleeding and laboratory tests have been developed to determine the presence of such defects. This review will briefly discuss the usual initial approach to the bleeding patient and then focus on non-surgical bleeding with normal platelet numbers and coagulation screening.
INITIAL ASSESSMENT OF THE BLEEDING PATIENT
Along with the resuscitative measures, identifying the source of bleeding and associated causes of bleeding is the mainstay of management. Prompt blood volume replacement with activation of the institutional massive transfusion protocol will be needed in case of excessive bleeding. If the anatomical site of bleeding is identified, local Review Proceedings of Singapore Healthcare  Volume 23  Number 1  2014 Full blood count (FBC)
• Haemoglobin level may give an indication of the severity of bleeding and its onset, providing guidance on red blood cell transfusion. Maintaining an adequate haematocrit level also optimises the function of platelets. • Thrombocytopaenia can be the primary cause of bleeding or secondary to consumption or dilution following massive blood transfusion. In most instances, a platelet level of at least 50 x 10 9 /L is desired for adequate control of bleeding 1 . • Total white blood cell count and the differential count may indicate an underlying white blood cell disorders (e.g. acute leukaemia) which may be associated with thrombocytopenia or a coagulopathy (e.g. acute promyelocytic leukemia).
Blood grouping and cross-match
• Patient should be transfused with ABO/Rh D matched blood products whenever possible. Emergency blood transfusion may be done with group O/ Rh D negative red blood cells but patient's blood group identification and cross-matching should be done as soon as possible so that matched blood products can subsequently be given.
Prothrombin time (PT)
• Assesses the integrity of extrinsic and common coagulation pathway and PT will be prolonged if there is factor VII, V, X, II, I deficiency. • An isolated PT indicates factor VII deficiency.
Activated partial thromboplastin time (aPTT) • Assesses the integrity of intrinsic and common coagulation pathway and aPTT
will be prolonged if there is factor XII, XI, IX, VIII, V, X, II, I deficiency, HMWK or prekallikrein deficiency. and surgical measures should be applied without delay whenever possible. A detailed clinical history including drug history (e.g. antiplatelets and anticoagulants, their dose and the time taken) is crucial for optimal management. If the bleeding is spontaneous or exceeds the expected loss due to surgery, an underlying coagulation or platelet disorder may be suspected. Initial laboratory tests recommended in a bleeding patient with the rationale for doing them are shown in Table  1 . These laboratory assays should be done as early as possible while stabilizing the patient. Should an abnormality be evident, replacement therapy with the appropriate blood or haemostatic product would be paramount to stemming further bleeding. The tests may need to be repeated at a later time for further management of the patient, as the results of the initial assays may be influenced by the use of blood products during resuscitation process.
THE BLEEDING PATIENT WITH A NORMAL COAGULATION SCREEN AND PLATELET COUNT
Coagulation abnormalities may be suspected in instances when bleeding persists despite interventional measures. A normal platelet count and initial coagulation screen does not exclude this possibility. Two possibilities should be considered: (a) the normal prothrombin time (PT) and activated partial thromboplastic time (aPTT) result being a false negative result or (b) the patient having coagulation disorders which cannot be detected by PT and aPTT testing.
Normal PT and aPTT Being False Negative Results
The clotting factors involved in the series of reactions, determining the PT or aPTT and the components of haemostatic pathways that fall outside the limits of PT and aPTT are shown in Fig. 1 .
HWMK: high molecular weight kininogen Prothrombin time and aPTT can be affected by many pre-analytical, analytical and post-analytical factors as described in Table 2 . Most aPTT reagents are sensitive enough to detect mild haemophilia A and B. Factor VIII and IX levels of less than 30-40% will usually result in prolongation of the aPTT. However, some reagents with low sensitivity will give rise to normal aPTT and the diagnosis will be missed if specific factor assays are not performed 3, 4 . Similarly, PT results can vary according to the different types of thromboplastin (human versus bovine) used and different dilution methods 5 . Mild factor VII deficiency may not lead to prolongation of PT in laboratories using bovine thromboplastin. The choice of reagents and instrument calibration along with the implementation of internal and external quality assurance programs are essential to produce meaningful and reliable laboratory results. APTT is more prolonged in clotting factor deficiencies involving the proximal part of the intrinsic pathway, like factor XII, factor IX or X, with the exception of factor XI. This is in contrast to deficiencies involving the distal part of the pathway, like thrombin or fibrinogen. Therefore, a single clotting factor deficiency like factor XI deficiency or mild thrombin or fibrinogen deficiency could still be possible in a patient with normal PT and aPTT 6 . Excessive bleeding due to mild coagulation disorders are however uncommon.
In addition, clerical and transcriptional errors can still occur when the results are transferred from the instruments to patients' reports. Therefore, repeating the test with a fresh sample may sometimes be necessary to confirm the test result.
Coagulation Disorders with Normal PT and aPTT Platelet Function Disorders and von Willebrand Disease (vWD)
The PT or aPTT does not assess primary haemostasis involving platelets and von Willebrand factors or secondary haemostasis involving fibrin stabilization and the fibrinolytic system. Coagulation disorders involving platelets, von Willebrand factor (vWF), fibrin stabilization process and fibrinolytic system should be considered if the factors discussed in the earlier section have been excluded.
Bleeding manifestations due to primary haemostasis disorders are mainly mucocutaneous bleeding, like gum bleeding, epistaxis, easy bruising with petechiae and purpura and genitourinary tract bleeding especially menorrhagia in women 7 .
As platelet dysfunction and vWD are autosomal disorders a detailed family history including consanguinity should be explored. A detailed drug history is also important and should include questions on the use of antiplatelets and traditional medicines (e.g. dong quai, garlic, ginger, tumeric, etc.) with antiplatelet effect.
If the patient is suspected to have platelet dysfunction, platelet function tests can be carried out by light transmission aggregometry to confirm the diagnosis. Further investigations with flow cytometry, assays of released nucleotides from platelet granules, electron microscopy and molecular genetic studies 8 to sub-categorise the different types of platelet function disorders can be performed but some of these tests are currently not available in Singapore.
Quantitative and qualitative disorders of von
Willebrand factor can also give rise to similar bleeding manifestations as platelet dysfunction except for type 3 vWD which is usually associated with moderate to severe Factor VIII deficiency and may be misdiagnosed as Haemophilia A. Von Willebrand disease is the most common inherited bleeding disorder affecting about 1% of the population with majority being asymptomatic 9 . The vWF acts as a bridge between platelets and vascular endothelium 10 . It is stored and secreted from the endothelial cells and megakaryocytes 11, 12 . It also serves as a carrier molecule for coagulation factor VIII, the half-life of which will be reduced in case of severe vWF deficiency 13 . In mild type 1 vWD and certain type 2 vWDs (such as type 2A, 2B and 2M) factor VIII levels may be normal, and hence, aPTT will not be prolonged. Autosomal dominant pattern of inheritance and the detailed family and clinical history should prompt the clinician to suspect the disorder. Further specific investigations, like vWF antigen assay by enzyme linked immunosorbent assay (ELISA), ristocetin cofactor activity, collagen binding activity and vWF multimer assays can be performed to confirm the diagnosis [14] [15] [16] [17] .
Factor XIII Deficiency and Disorders of Fibrinolytic System
Prothrombin time and aPTT tests provide information about the integrity of the coagulation system up to the formation of fibrin strands in the plasma. In vivo, a series of changes occur after initial formation of fibrin clot to achieve sustained haemostasis. A burst of thrombin formation occurs after the initial fibrin clot with activation of factor XIII (fibrin stabilizing factor). Factor XIII is a transglutaminase with A and B subunits, existing as heterotetramers and B2 homodimers in plasma Proceedings of Singapore Healthcare  Volume 23  Number 1  2014 or A2 homodimers in platelets and monocytes. It plays a role in secondary haemostasis by crosslinking the fibrin chains, strengthening and stabilizing the clot formed. Patients with factor XIII deficiency usually present with delayed secondary bleeding, like post-operative bleeding, umbilical stump bleeding in neonates or soft tissue and intracranial bleeding. Factor XIII deficiency can be congenital (autosomal recessive) or acquired. The prevalence of congenital Factor XIII deficiency is about 1 in 3-5 million population 18 and that of acquired is unknown with 36 cases reported in the literature 19, 20 . Acquired Factor XIII deficiency can be associated with autoimmune disorders like systemic lupus erythematosus, certain drugs like isoniazid, and malignancies 20 . Platelet count, PT, aPTT, fibrinogen levels will be normal in these patients. The condition can be rapidly fatal due to excessive blood loss and hence, clinical suspicion and awareness of the condition is the key in the management of these patients. Diagnosis can be confirmed by performing factor XIII assays qualitatively or quantitatively. Qualitative factor XIII assays are done by assessing the clot solubility in 5 M urea solution or 1% monochloroacetic acid solution 21 . It can detect severe factor XIII deficiency of <1% and is widely available in most laboratories, although standardisation of the techniques may be poor. Quantitative measurement can be performed by amine incorporation assays or ammonia release assays 22, 23 . Factor XIII antigens and subunit specific anti-factor XIII antibodies in case of suspected acquired deficiency, can be detected by ELISA and Western blotting assays. Genetic mutational analysis may be useful for screening of the family members 24, 25 .
The fibrinolytic system serves as a counter-check mechanism to the coagulation pathway preventing excessive clot formation and thrombosis. The main components of the fibrinolytic system are plasminogen and plasmin, the latter being the active form of the former, degrading fibrin to fibrin degradation products. There are other components which act as activators and inhibitors of plasmin, to maintain the balance between haemostasis and thrombosis 26 . Overexpression of the activators like plasminogen activators or deficiency of inhibitors like plasminogen activator inhibitor and alpha-2 antiplasmin can lead to hyperfibrinolytic state, resulting in bleeding 27, 28 . Hyperfibrinolytic disorders again can be primary (congenital) which is very rare, and secondary, being associated with trauma, malignancies, liver failure, etc. which is more common 29 . In severe fibrinolysis with fibrinogen deficiency, PT and aPTT may be prolonged but normal PT and aPTT do not exclude these disorders.
Vascular and Connective Tissue Disorders
Lastly, excessive bleeding can be as a result of vascular or cutaneous disorders such as Ehlers-Danlos Syndrome, connective tissue disorders, vasculitis, scurvy, and senile purpura. Patients with these conditions will have a normal haemostatic profile.
Other Conditions Associated with Variable PT/ aPTT Results

New Oral Anticoagulants and Low Molecular Weight Heparin
The armamentarium of anticoagulants has recently been expanded with the advent of new oral anticoagulants (NOACs) which are direct inhibitors of active clotting factors. The conventional unfractionated heparin and vitamin K antagonists (e.g. warfarin) will prolong aPTT and PT proportionately according to the plasma levels. However, new oral anticoagulants like dabigatran and rivaroxaban will result in variable prolongation of aPTT and PT with dabigatran mainly affecting the aPTT and rivaroxaban affecting PT. Some reagents are not sensitive enough to detect the effect of the NOACs and aPTT and PT may be completely normal at therapeutic doses 30, 31 . Similarly, low molecular weight heparins do not prolong aPTT significantly and the levels cannot be monitored by aPTT. Specific assays like dilute thrombin time or anti-Xa assay calibrated for the compound interested, to check the presence of drugs need to be done if it is clinically indicated.
CONCLUSION
In summary, the approach to a bleeding patient with normal PT and aPTT includes the basic steps of excluding surgical causes of bleeding, false negative laboratory tests and further investigations for the disorders which evade of the scope of PT and aPTT, if relevant (Fig. 2) . Clinical history, family history and a careful drug history are essential to make a correct diagnosis and to avoid over-investigating the patient for rare disorders. Awareness of the pattern of prevalence and incidence of rare disorders in a local population will provide the clinician with the necessary guidance to choose relevant investigations among the many available. Laboratory tests are performed in a state which mimicks the in-vivo environment as much as possible. However, one must note that haemostatic changes in a bleeding patient occur as a dynamic continuum and results of the laboratory tests usually provide only a snapshot of the state of haemostasis. Therefore, it is highly important to be able to interpret the results in combination with the clinical judgment of the physician. 16. Favaloro EJ, Grispo L, Exner T, Koutts J. Development of a simple collagen based ELISA assay aids in the diagnosis of, and permits sensitive discrimination between type I and type II, von Willebrand's disease. Blood Coagul Fibrinolysis 1991;2(2):285-91 doi: 10.1097/00001721-199104000-00011. 
